Skip to main content

Caris Life Sciences, Inc. (CAI) Stock

Caris Life Sciences, Inc. Stock Details, Movements and Public Alerts

Stock Details

Caris Life Sciences, Inc. (CAI), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $18.05. Over the past 52 weeks, it has ranged between $16.28 and $42.50. This places the current price at 42.5% of its 52-week high and 10.9% above its 52-week low. Recent trading volume was recorded at 2,720,224. The 14-day Relative Strength Index (RSI) stands at 34.64, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $26.30 by 31.37%. The MACD histogram is -0.29, indicating bearish momentum (MACD Line: -1.34, Signal Line: -1.06). There is currently 1 active alert set for CAI by users.

52-Week Range

$42.50 - $16.28

-57.53% from high · +10.87% from low

Avg Daily Volume

2,476,852

20-day average

100-day avg: 1,833,150

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

48.85

Price to Book

8.84

EV/EBITDA

69.83

EPS (TTM)

-$3.22

Price to Sales

6.28

Q:How is CAI valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is CAI's risk profile compared to the market?
Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

-8.39%

Operating Margin

30.19%

EBITDA

$67.73M

Return on Equity

-45.37%

Return on Assets

3.84%

Revenue Growth (YoY)

125.40%

Q:How profitable and efficient is CAI's business model?
Caris Life Sciences, Inc. achieves a profit margin of -8.39%, meaning it retains $-8.39 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 30.19% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -45.37% and ROA at 3.84%, the company achieves moderate returns on invested capital.
Q:What are CAI's recent growth trends?
Caris Life Sciences, Inc.'s revenue grew by 125.40% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$5.1B

Revenue (TTM)

$812.03M

Revenue/Share (TTM)

$4.86

Shares Outstanding

282.58M

Book Value/Share

$2.04

Asset Type

EQUITY

Q:What is CAI's market capitalization and position?
Caris Life Sciences, Inc. has a market capitalization of $5.1B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 282.58M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does CAI's price compare to its book value?
Caris Life Sciences, Inc.'s book value per share is $2.04, while the current stock price is $18.05, resulting in a price-to-book (P/B) ratio of 8.84. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$31.00

71.75% upside potential

Analyst Recommendations

Strong Buy

1

Buy

7

Hold

1

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for CAI?
9 analysts cover CAI with 89% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $31.00 implies 71.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on CAI?
Current analyst recommendations:1 Strong Buy, 7 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Apr 12, 2026, 02:00 AM

Technical Indicators

RSI (14-day)

34.64

Neutral

50-Day Moving Average

$26.30

-31.37% below MA-50

MACD Line

-1.34

MACD Signal

-1.06

MACD Histogram

-0.29

Bearish

Q:What does CAI's RSI value tell investors?
The RSI (Relative Strength Index) for CAI is currently 34.64, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret CAI's MACD and moving average crossovers?
MACD analysis shows the MACD line at -1.34 below the signal line at -1.06, with histogram at -0.29. This bearish crossover indicates downward pressure.

Indicators last updated: Feb 11, 2026, 12:38 AM

Active Alerts

Alert Condition
Price falls below
Threshold
$14.00
Created
Nov 21, 2025, 03:03 PM

Stay Ahead of the Market with Caris Life Sciences, Inc. Alerts

Set up price alerts for Caris Life Sciences, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.